

University of Groningen

Antimicrobial Susceptibility and Genetic Prevalence of Extended-Spectrum β -Lactamases in Gram-Negative Rods Isolated from Clinical Specimens in Pakistan

Idrees, Muhammad Mubashar; Rimsha, Rimsha; Idrees, Muhammad Daoud; Saeed, Ali

Published in:
Antibiotics

DOI:
[10.3390/antibiotics12010029](https://doi.org/10.3390/antibiotics12010029)

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2023

[Link to publication in University of Groningen/UMCG research database](#)

Citation for published version (APA):

Idrees, M. M., Rimsha, R., Idrees, M. D., & Saeed, A. (2023). Antimicrobial Susceptibility and Genetic Prevalence of Extended-Spectrum β -Lactamases in Gram-Negative Rods Isolated from Clinical Specimens in Pakistan. *Antibiotics*, 12(1), Article 29. <https://doi.org/10.3390/antibiotics12010029>

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Article

Antimicrobial Susceptibility and Genetic Prevalence of Extended-Spectrum β -Lactamases in Gram-Negative Rods Isolated from Clinical Specimens in Pakistan

Muhammad Mubashar Idrees ^{1,2,3} , Rimsha Rimsha ⁴, Muhammad Daoud Idrees ⁵ and Ali Saeed ^{1,6,*}¹ Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan 60800, Pakistan² Multan Institute of Kidney Diseases (MIKD), Multan 60800, Pakistan³ Department of Medical Laboratory Technology, Faculty of Medicine and Allied Health Sciences, The Islamia University of Bahawalpur, Bahawalpur 63100, Pakistan⁴ National Institute of Food Science and Technology, University of Agriculture, Faisalabad 38000, Pakistan⁵ Department of Biochemistry, Bahauddin Zakariya University, Multan 60800, Pakistan⁶ Department of Pediatric Oncology & Medical Microbiology, University Medical Center Groningen, University of Groningen, P.O. Box 72, 9700 AB Groningen, The Netherlands

* Correspondence: alisaheed@bzu.edu.pk or dralisaheed84@gmail.com; Tel.: +92-(0)-32-2661-6269

Abstract: The prevalence of extended-spectrum β -lactamase (ESBL) genes has increased remarkably, resulting in multidrug-resistant gram-negative rods (GNRs) in clinical specimens. This cross-sectional study aimed to determine the antimicrobial susceptibility of ESBL-producing GNRs and its correlation with corresponding genes. Two hundred and seventy-two ($n = 272$) samples were evaluated for the molecular identification of ESBL genes by polymerase chain reaction after confirmation with the modified double-disc synergy test. *E. coli* 64.0% ($n = 174$) was the most prevalent ESBL producer, followed by *Klebsiella* species 27.2% ($n =$ seventy-four), *Acinetobacter* species 6.6% ($n =$ eighteen) and others 2.2% ($n =$ six). These ESBL-producing isolates showed resistance to β -lactam antibiotics, i.e., sulbactam/cefoperazone (41.5%), piperacillin/tazobactam (39.3%), meropenem (36.0%), imipenem (34.2%) and non- β -lactam antibiotics, i.e., nalidixic acid (89.0%), co-trimoxazole (84.9%), ciprofloxacin (82.4%), gentamicin (46.3%), nitrofurantoin (24.6%), amikacin (19.9%) and fosfomycin (19.9%). The incidences of the ESBLs-producing genes *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV} were 91.2%, 61.8%, 39.3% and 17.6%, respectively. Among nine multiple-gene combinations, *bla*_{CTX-M} + *bla*_{TEM} (30.5%) was the most prevalent combination, followed by *bla*_{CTX-M} + *bla*_{OXA} + *bla*_{TEM} (14.0%), *bla*_{CTX-M} + *bla*_{OXA} (13.6%), *bla*_{CTX-M} + *bla*_{TEM} + *bla*_{SHV} (7.0%), *bla*_{CTX-M} + *bla*_{SHV} (2.2%), *bla*_{CTX-M} + *bla*_{OXA} + *bla*_{SHV} (2.2%) and *bla*_{OXA} + *bla*_{TEM} (1.8%). ESBLs producing GNRs carrying *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV} showed resistances to β -lactam antibiotics, i.e., ampicillin, amoxicillin-clavulanic acid, cefotaxime and ceftazidime but were susceptible to carbapenems (meropenem and imipenem), β -lactam- β -lactamase inhibitor combination (piperacillin/tazobactam) and non- β -lactam antibiotics i.e., aminoglycoside (amikacin and gentamicin), nitrofurantoin and fosfomycin. These antibiotics that demonstrated activity may be used to treat infections in clinical settings.

Keywords: extended-spectrum β -lactamases (ESBLs); gram-negative bacteria; CTX-M; TEM; SHV; OXA; disk diffusion method; polymerase chain reaction (PCR)



Citation: Idrees, M.M.; Rimsha, R.; Idrees, M.D.; Saeed, A. Antimicrobial Susceptibility and Genetic Prevalence of Extended-Spectrum β -Lactamases in Gram-Negative Rods Isolated from Clinical Specimens in Pakistan.

Antibiotics **2023**, *12*, 29.

[https://doi.org/](https://doi.org/10.3390/antibiotics12010029)

10.3390/antibiotics12010029

Academic Editor: Krisztina M. Papp-Wallace

Received: 30 September 2022

Revised: 20 December 2022

Accepted: 21 December 2022

Published: 24 December 2022



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

β -lactamases are mainly plasmid-mediated enzymes produced by some gram-negative rod-shaped bacteria that cause antimicrobial resistance against different antimicrobial groups, i.e., penicillin (ampicillin), expanded-spectrum cephalosporins (cefotaxime and ceftazidime) and monobactam (aztreonam) [1,2]. β -lactamases play a vital role in resisting or protecting gram-negative bacteria (GNB) against β -lactam antibiotics by breaking their β -lactam ring, leading to the ineffectiveness of β -lactam antibiotics [3,4]. The worldwide

incidence of GNB-producing extended-spectrum β -lactamases (ESBLs) has remarkably increased in urinary tract infections (UTI) both in community and clinical settings and is certainly a big therapeutic challenge [5–7]. Carbapenemases, AmpCs and ESBLs are more common β -lactamases produced by GNB. Originally, *bla*_{TEM-1} was a plasmid-based β -Lactamase (*bla*) gene detected in the 1960s [8]. After this, a group of ESBL-coding genes were identified in *Klebsiella pneumoniae* and *Serratia marcescens* in 1983, due to a point mutation in the *bla*_{TEM} and *bla*_{SHV} genes [9]. Previously, about 600 types of β -Lactamases existed that were resistant to β -Lactamase inhibitors, i.e., sulbactam, clavulanic acid and tazobactam; these included *bla*_{SHV}, *bla*_{TEM}, *bla*_{OXA} and *bla*_{CTX-M} [10,11]. β -Lactamases are divided into four classes based on their protein homology classes. A (TEM, SHV and CTX-M), C (AmpC) and D (OXA) are serine-based β -Lactamase and group B are metallo- β -lactamases [12]. *bla*_{TEM} and *bla*_{SHV} were found to be common genotypes in GNB-producing ESBLs [13]. Nevertheless, the prevalence of the *bla*_{CTX-M} gene (class A ESBLs) has increased, and it is the predominant genotype found worldwide [14]. The CTX-M-based ESBLs have higher catalytic activities against cefotaxime than ceftazidime [2,15]. Strains with CTX-M-type ESBLs are commonly associated with a resistance to aminoglycosides and fluoroquinolones, but in addition, trimethoprim/sulfamethoxazole and tetracycline are resistant in strains with the SHV- and TEM-type ESBLs [16,17].

The overuse of antibiotics, inappropriate hygienic practices in clinical settings and a lack of continuous monitoring of drug-resistance patterns have led to an environment for the emergence and uncontrolled dissemination of genes encoding AmpC and ESBL enzymes [18].

It is an alarming situation in clinical settings to treat and overcome infections caused by ESBL-producing pathogens that possess resistances to commonly used antibiotics. There is a lack of awareness in both the population and health care workers about the prevalence of these pathogens and the potential ramifications to controlling these infections [19]. The incidence of ESBL-producing pathogens is tremendously increasing due to lack of proper laboratory diagnosis, reporting and preventive measures in our clinical settings [20,21]. The World Health Organization (WHO) has shown a serious concern in the increase of antibiotic resistance in developing countries, especially Pakistan, and has asked for them to overcome this issue [2]. Different research groups have conducted their studies in different regions of Pakistan [22] such as Lahore (2022) [3], Timurgara [4] and Islamabad [5], but no studies were conducted in Multan, located in South Punjab, Pakistan. Thus, the importance of this study is due to lack of epidemiological data and the prevalence of ESBL producers and their antimicrobial-susceptibility patterns in our population. In view of this, the study was conducted to find out the susceptibility profiles of ESBL-producing isolates to various antibiotics to treat infections caused by the ESBL-producing isolates. Moreover, the prevalences of the corresponding ESBL genes (*bla*_{CTX-M}, *bla*_{OXA}, *bla*_{TEM} and *bla*_{SHV}) among clinical isolates in the Multan Institute of Kidney Disease Hospital, Multan, Pakistan was evaluated.

2. Results

2.1. Socio-Demographic Data and Distribution of ESBL-Producing Bacterial Isolates

A total of two hundred and seventy-two ($n = 272$) ESBL-producing clinical isolates were isolated. By sample type, 72.8% ($n = 198$) were collected from urine, 6.3% ($n = 17$) from blood, 5.9% ($n = 16$) from pus, 4.8% ($n = 13$) from throat aspiration, 2.9% ($n = 8$) from CVC Tip, 1.8% ($n = 5$) from sputum, 1.5% ($n = 4$) from PCN, 1.5% ($n = 4$) from bronchial aspiration and 2.6% ($n = 7$) from others (ascitic fluid and cerebrospinal fluids). In total, 50.7% ($n = 138$) isolates were identified in males, followed by females 49.3% ($n = 134$). The prevalence of ESBLs was more abundant in out-patients (OPD) at 45.2% ($n = 123$), followed by 21.3% ($n = 58$) from nephrology, 19.1% ($n = 52$) from urology, 9.6% ($n = 26$) from emergency and 4.8% ($n = 13$) from the intensive-care unit (ICU). *Escherichia coli* at 64.0% ($n = 174$) were the most prevalent ESBL-producing bacterial isolates identified in this study, followed by *Klebsiella* species 27.2% ($n = 74$), *Acinetobacter* species 6.6% ($n = 18$) and

others (*Salmonella*, *Stenotrophomonas* species, *Serratia*) 2.2% ($n = 6$) (Table 1) and detailed information are available in the supplementary data file.

Table 1. Socio-demographic data of clinically isolated bacteria.

	Age Sample Size %	0–9 ($n = 24$) 8.8	10–19 ($n = 27$) 9.9	20–29 ($n = 22$) 8.1	30–39 ($n = 30$) 11.0	40–49 ($n = 38$) 14.0	50–59 ($n = 55$) 20.0	60–69 ($n = 40$) 14.7	>70 ($n = 36$) 13.2
Gender	Male ($n = 138$) 50.7%	11 (8.0)	14 (10.1)	3 (2.2)	14 (10.1)	18 (13.0)	24 (17.4)	26 (18.8)	28 (20.3)
	Female ($n = 134$) 49.3%	13 (9.7)	13 (9.7)	19 (14.2)	16 (11.9)	20 (14.9)	31 (23.1)	14 (10.4)	8 (6.0)
Ward	OPD ($n = 123$) 45.2%	15 (12.5)	10 (8.1)	7 (5.7)	15 (12.2)	21 (17.1)	24 (19.5)	16 (13.0)	15 (12.2)
	Nephrology ($n = 58$) 21.3%	0 (0.0)	2 (3.4)	9 (15.5)	9 (15.5)	8 (13.8)	13 (22.4)	8 (13.80)	9 (15.5)
	Emergency ($n = 26$) 9.6%	1 (3.8)	4 (15.4)	1 (3.8)	1 (3.8)	1 (3.8)	9 (34.6)	4 (15.4)	5 (19.2)
	ICU ($n = 13$) 4.8%	1 (7.7)	4 (30.8)	3 (23.1)	0 (0.0)	0 (0.0)	1 (7.7)	1 (7.7)	3 (23.1)
	Urology ($n = 52$) 19.1%	7 (13.5)	7 (13.5)	2 (3.8)	5 (9.6)	8 (15.4)	8 (15.4)	11 (21.2)	4 (7.7)
	Bacterial isolate	<i>Escherichia coli</i> ($n = 174$) 64.0	14 (8.0)	14 (8.0)	11 (6.3)	20 (11.5)	28 (16.1)	40 (23.0)	22 (12.6)
	<i>Klebsiella spp.</i> ($n = 74$) 27.2	6 (8.1)	8 (10.8)	6 (8.1)	8 (10.8)	6 (8.1)	14 (18.9)	16 (21.6)	10 (13.5)
	<i>Acinetobacter spp.</i> ($n = 18$) 6.6	4 (22.2)	3 (16.7)	4 (22.2)	2 (11.1)	4 (22.2)	1 (5.6)	0 (0.0)	0 (0.0)
	Others ($n = 6$) 2.2	0 (0.0)	2 (33.3)	1 (16.7)	0 (0.0)	0 (0.0)	0 (0.0)	2 (33.3)	1 (16.7)
Sample collection Source	Urine ($n = 198$) 72.8%	16 (8.1)	17 (8.6)	15 (7.6)	21 (10.6)	31 (15.7)	39 (19.7)	33 (16.7)	26 (13.1)
	Blood ($n = 17$) 6.3%	1 (5.9)	4 (23.5)	1 (5.9)	1 (5.9)	3 (17.6)	4 (23.5)	1 (5.9)	2 (11.8)
	Pus ($n = 16$) 5.9%	0 (0.0)	1 (6.3)	2 (12.5)	1 (6.3)	1 (6.3)	6 (37.5)	2 (12.5)	3 (18.8)
	Throat aspiration ($n = 13$) 4.8%	4 (30.8)	2 (15.4)	1 (7.5)	1 (7.7)	1 (7.7)	1 (7.7)	1 (7.7)	2 (15.4)
	CVC Tip ($n = 8$) 2.9%	1 (12.5)	0 (0.0)	2 (25.0)	1 (12.5)	2 (25.0)	0 (0.0)	1 (12.5)	1 (12.5)
	Sputum ($n = 5$) 1.8%	0 (0.0)	1 (20.0)	0 (0.0)	1 (20.0)	0 (0.0)	2 (40.0)	0 (0.0)	1 (20.0)
	PCN ($n = 4$) 1.5%	0 (0.0)	0 (0.0)	0 (0.0)	2 (50.0)	0 (0.0)	1 (25.0)	1 (25.0)	0 (0.0)
	Bronchial aspiration ($n = 4$) 1.5%	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)	0 (0.0)	0 (0.0)	1 (25.0)	1 (25.0)
	Others ($n = 7$) 2.6%	1 (14.3)	2 (28.6)	1 (14.3)	1 (14.3)	0 (0.0)	2 (28.6)	0 (0.0)	0 (0.0)

OPD = outpatient, ICU = intensive-care unit, PCN = Percutaneous nephrostomy, CVC = central venous catheters.

2.2. Susceptibility of ESBL-Producing Gram-Negative Rods (GNRs) to Antibiotics

The activities of different antibiotics against GNB such as *Escherichia coli*, *Klebsiella* species, *Acinetobacter* species and others (*Salmonella*, *Stenotrophomonas* species, *Serratia*) were tested in this study. Resistance was the highest for nalidixic acid, followed by NOR > SXT > CIP > G > SCF > TZP > IPM > MEM > F > AK > FOS against GNRs (Table 2). The GNRs were most susceptible to the following agents from highest to lowest: FOS > AK > F > MEM > IPM > TZP > SCF > G > CIP > SXT > NOR and NA. In conclusion, ESBL producers possessed the lowest MICs for FOS, AK, F, MEM, IPM, TZP, SCF and G. Thus, these agents

may potentially be treatment options. Conversely, NA, NOR, SXT and CIP showed higher rates of resistance against GNRs, so they should not be used for treatment (Table 2).

Table 2. Antimicrobial susceptibility testing against ESBL-producing *Escherichia coli*, *Klebsiella* species, *Acinetobacter* species and others.

Antibiotics	<i>Escherichia coli</i> n = 174			<i>Klebsiella</i> Species n = 74			<i>Acinetobacter</i> Species n = 18			Others n = 6			Total n = 272		
	R	I	S	R	I	S	R	I	S	R	I	S	R	I	S
TZP	45 (25.9)	1 (0.6)	128 (73.6)	43 (58.1)	1 (1.4)	30 (40.5)	17 (94.4)	0 (0.0)	1 (5.6)	2 (33.3)	0 (0.0)	4 (66.7)	107 (39.3)	2 (0.7)	163 (59.9)
MEM	33 (19.0)	1 (0.6)	140 (80.5)	46 (62.2)	0 (0.0)	28 (37.8)	17 (94.4)	0 (0.0)	1 (5.6)	2 (33.3)	0 (0.0)	4 (66.7)	98 (36.0)	1 (0.4)	173 (63.6)
IPM	35 (20.1)	2 (1.1)	137 (78.7)	44 (59.5)	0 (0.0)	30 (40.5)	17 (94.4)	0 (0.0)	1 (5.6)	2 (33.3)	0 (0.0)	4 (66.7)	98 (36.0)	2 (0.7)	172 (63.2)
G	63 (36.2)	1 (0.6)	110 (63.2)	45 (60.8)	0 (0.0)	29 (39.2)	15 (83.3)	0 (0.0)	3 (16.7)	3 (50.0)	0 (0.0)	3 (50.0)	126 (46.3)	1 (0.4)	145 (53.3)
AK	19 (10.9)	5 (2.9)	150 (86.2)	31 (41.9)	3 (4.1)	40 (54.1)	15 (83.3)	0 (0.0)	3 (16.7)	2 (33.3)	0 (0.0)	4 (66.7)	67 (24.6)	8 (2.9)	197 (72.4)
NA	156 (89.7)	3 (1.7)	15 (8.6)	64 (86.5)	0 (0.0)	10 (13.5)	17 (94.4)	0 (0.0)	1 (5.6)	5 (83.3)	0 (0.0)	1 (16.7)	242 (89.0)	3 (1.1)	27 (9.9)
NOR	150 (86.2)	0 (0.0)	24 (13.8)	58 (78.4)	1 (1.4)	15 (20.3)	17 (94.4)	0 (0.0)	1 (5.6)	6 (100.0)	0 (0.0)	0 (0.0)	231 (84.9)	1 (0.4)	40 (14.7)
CIP	141 (81.0)	0 (0.0)	33 (19.0)	61 (82.4)	0 (0.0)	13 (17.6)	17 (94.4)	0 (0.0)	1 (5.6)	5 (83.3)	0 (0.0)	1 (16.7)	234 (82.4)	0 (0.0)	48 (17.6)
SXT	146 (83.9)	0 (0.0)	28 (16.1)	64 (86.5)	0 (0.0)	10 (13.5)	17 (94.4)	0 (0.0)	1 (5.6)	4 (66.7)	0 (0.0)	2 (33.3)	231 (84.9)	0 (0.0)	41 (15.1)
F	30 (17.2)	3 (1.7)	141 (81.0)	45 (60.8)	2 (2.7)	27 (36.5)	15 (83.3)	0 (0.0)	3 (16.7)	3 (50.0)	0 (0.0)	3 (50.0)	93 (34.2)	5 (1.8)	174 (64.0)
SCF	50 (28.7)	2 (1.1)	122 (70.1)	45 (60.8)	1 (1.4)	28 (37.8)	16 (88.9)	1 (5.6)	1 (5.6)	2 (33.3)	0 (0.0)	4 (66.7)	113 (41.5)	4 (1.5)	155 (57.0)
FOS	8 (4.6)	0 (0.0)	166 (95.4)	28 (37.8)	4 (5.4)	42 (56.8)	15 (83.3)	1 (5.6)	2 (11.1)	3 (50.0)	0 (0.0)	3 (50.0)	54 (19.9)	5 (1.8)	213 (78.3)

R = resistant, I = intermediate, S = susceptible, NA = nalidixic acid, SXT = co-trimoxazole, CIP = ciprofloxacin, CN = gentamicin, SCF = sulbactam/cefoperazone, TZP = piperacillin/tazobactam, MEM = meropenem, IPM = imipenem, F = nitrofurantoin, AK = amikacin, FOS = fosfomicin.

2.3. Susceptibility of *Escherichia coli* to Various Antibiotics

E. coli (64.0%, n = 174/272) was the most prevalent bacterial species found among the tested ESBL-producing clinical isolates, and its susceptibility to antibiotics was as follows: FOS > AK > F > MEM > IPM > TZP > SCF > G > CIP > SXT > NOR and NA. The resistance rates of *E. coli* against antibiotics were NA > NOR > SXT > CIP > G > SCF > TZP > IPM > MEM > F > AK > FOS. The most effective drugs against ESBLs producing *E. coli* were FOS, AK, F, MEM, IPM, TZP and SCF and G. NA, NOR, SXT and CIP were not effective (Table 2).

2.4. Susceptibility of *Klebsiella* Species to Various Antibiotics

Klebsiella species (27.0%, n = 74/272) were the second-most-prevalent organism identified in the tested ESBL-producing bacteria after *E. coli*. The effectiveness rates of antibiotics against *Klebsiella* species were as follows: FOS > AK > IPM, TZP > G > MEM, SCF > F > NOR > CIP > SXT, NA. FOS and AK were the most effective drugs against these ESBL-producing *Klebsiella* species (Table 2).

2.5. Susceptibility of *Acinetobacter* Species and Others to Various Antibiotics

Acinetobacter species (6.6%, n = 18) were the least-prevalent organisms as compared with *E. coli* and *Klebsiella* species. *Acinetobacter* species showed high rates of resistance against all antibiotics used in this study.

A few strains of *Salmonella*, *Stenotrophomonas* species and *Serratia* (2.2%, $n = 6$) were identified among the ESBLs producing bacteria, and they were more susceptible to AK, IPM, TZP, MEM, SCF, F, FOS and G. These isolates were more resistant to SXT, CIP, NOR and NA in this study (Table 2).

2.6. Prevalence of *bla*_{CTX-M}, *bla*_{OXA}, *bla*_{TEM} and *bla*_{SHV} among GNRs

*bla*_{CTX-M} (91.2%, $n = 248/272$) was the most prevalent gene coding for ESBL production among clinical isolates, followed by *bla*_{TEM} (61.8%, $n = 168/272$), *bla*_{OXA} (39.3%, $n = 107/272$) and *bla*_{SHV} (17.6%, $n = 48/272$). This study revealed that *bla*_{CTX-M} was the most significant gene among *E. coli*, *Klebsiella* species, *Acinetobacter* species and others, followed by *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV} (Table 3).

Table 3. Distribution of ESBL coding genes among GNB bacteria isolated from clinical specimens.

Bacterial Isolate N = 272		CTX-M $n = 248$ (91.2%)	OXA $n = 107$ (39.3%)	TEM $n = 168$ (61.8%)	SHV $n = 48$ (17.6%)	<i>p</i> -Value
<i>Escherichia coli</i>	Positive	160 (92.0)	71 (40.8)	105 (60.3)	25 (14.4)	0.00 *
	Negative	14 (8.0)	103 (59.2)	69 (39.7)	149 (85.6)	
<i>Klebsiella</i> species	Positive	68 (91.9)	30 (40.5)	46 (62.2)	18 (24.3)	0.00 *
	Negative	6 (8.1)	44 (59.5)	28 (37.8)	56 (75.7)	
<i>Acinetobacter</i> species	Positive	16 (88.9)	5 (27.8)	13 (72.2)	4 (22.2)	0.00 *
	Negative	2 (11.1)	13 (72.2)	5 (27.8)	14 (77.8)	
Others	Positive	4 (66.7)	1 (16.7)	4 (66.7)	1 (16.7)	0.00 *
	Negative	2 (33.3)	5 (83.7)	2 (33.3)	5 (83.7)	

* Prevalence of ESBLs coding genes (*bla*_{CTX-M}, *bla*_{OXA}, *bla*_{TEM}, and *bla*_{SHV}) in *E. coli*, *Klebsiella* species, *Acinetobacter* species and others (*Salmonella*, *Stenotrophomonas* species and *Serratia*).

2.7. Correlation between Antibiotic Resistance and ESBL Genes

Two hundred and seventy-two isolates were phenotypically positive for ESBLs; 270 were confirmed by PCR to have ESBL-coding genes alone or in combination and two were negative. The most common gene combinations among clinical isolates were *bla*_{CTX-M} and *bla*_{TEM} ($n = 83/270$), followed by various combinations of *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{SHV} and *bla*_{OXA}. All ESBLs-positive isolates showed resistance to β -lactam drugs (AMP, AMC, CTX and CAZ). In addition to β -lactam antibiotics, fluoroquinolones antibiotics (NA, NOR and CIP) were not effective against pathogens that possessed either *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTX-M} & *bla*_{SHV}, *bla*_{OXA} & *bla*_{TEM}, *bla*_{TEM} & *bla*_{SHV}, *bla*_{CTX-M} & *bla*_{OXA} & *bla*_{TEM}, *bla*_{CTX-M} & *bla*_{OXA} & *bla*_{SHV}, *bla*_{CTX-M} & *bla*_{TEM} & *bla*_{SHV}, *bla*_{OXA} & *bla*_{TEM} & *bla*_{SHV} or *bla*_{CTX-M} & *bla*_{TEM} & *bla*_{OXA} & *bla*_{SHV} (Table 4). There was not a single clinical isolate that possessed both the *bla*_{OXA} and *bla*_{SHV} genes.

Table 4. Antibiotic resistance and presence of ESBLs-coding genes among clinical isolates.

Genes	Total N (%)	Non- β -Lactam Antibiotics
<i>bla</i> _{CTX-M} + <i>bla</i> _{TEM}	83 (30.5)	-
<i>bla</i> _{CTX-M}	46 (16.9)	-
<i>bla</i> _{CTX-M} + <i>bla</i> _{OXA} + <i>bla</i> _{TEM}	38 (14.0)	NA, NOR, CIP
<i>bla</i> _{CTX-M} + <i>bla</i> _{OXA}	37 (13.6)	-
<i>bla</i> _{CTX-M} + <i>bla</i> _{TEM} + <i>bla</i> _{SHV}	19 (7.0)	SXT
<i>bla</i> _{CTX-M} + <i>bla</i> _{TEM} + <i>bla</i> _{OXA} + <i>bla</i> _{SHV}	13 (4.8)	NA, NOR, CIP, SXT,
<i>bla</i> _{TEM}	7 (2.6)	NA, NOR, CIP,

Table 4. Cont.

Genes	Total N (%)	Non-β-Lactam Antibiotics
<i>bla</i> _{OXA}	6 (2.2)	-
<i>bla</i> _{CTX-M} + <i>bla</i> _{SHV}	6 (2.2)	NA, NOR, CIP, SXT, F, SCF, FOS
<i>bla</i> _{CTX-M} + <i>bla</i> _{OXA} + <i>bla</i> _{SHV}	6 (2.2)	NA, NOR, CIP, SXT, F
<i>bla</i> _{OXA} + <i>bla</i> _{TEM}	5 (1.8)	NA, NOR, CIP, SXT
<i>bla</i> _{OXA} + <i>bla</i> _{TEM} + <i>bla</i> _{SHV}	2 (0.7)	MEM, IPM, G, AK, NA, NOR, CIP, SXT, SCF, F, FOS
Nil	2 (0.7)	NA, NOR, CIP
<i>bla</i> _{SHV}	1 (0.4)	MEM, IPM, NA, NOR, CIP, SXT, SCF
<i>bla</i> _{TEM} + <i>bla</i> _{SHV}	1 (0.4)	MEM, IPM, G, AK, NA, NOR, CIP, SXT, SCF, F, FOS
<i>bla</i> _{OXA} + <i>bla</i> _{SHV}	0	-

3. Discussion

The presence of ESBL-producing *Enterobacteriaceae* has emerged as a critical problem on a global scale. Infections caused by these multidrug-resistant organisms are associated with significant fatality rates and a limited number of treatment choices [23,24]. Many GNB produce ESBL enzymes that can hydrolyse cephalosporins and penicillins; clavulanic acid can inhibit them [25]. Several ESBL-producing GNRs are also multi-drug resistant to non-β-lactam antibiotics, including co-trimoxazole, nalidixic acid, norfloxacin, ciprofloxacin and amikacin. Resistance genes are often encoded by the same plasmids necessary to produce ESBL [26]. Our study revealed that *E. coli* ($n = 174/272$, 64%) was the most prevalent ESBLs-producing organism, followed by *Klebsiella* species ($n = 74/272$, 27.2%), *Acinetobacter* species ($n = 18/272$, 2.2%) and others, including *Salmonella*, *Stenotrophomonas* species and *Serratia* ($n = 6/272$, 2.2%). Our finding was confirmed by different authors who reported that *E. coli* and *Klebsiella* species were the most prevalent organism over others in Pakistan [27,28].

Our study found a high level of antibiotic resistance towards β-lactam antibiotics, including penicillin (resistance varied from 97% to 100% against amoxicillin/clavulanate and 100% against ampicillin) and cephalosporins (resistance varied from 91% to 100% against both cefotaxime and ceftazidime). Our findings were supported by different studies conducted in Argentina [29], Turkey [30], Algeria [28], Pakistan [31–33] and the United States [34]. The widespread and careless use of newer antibiotics, especially in the treatment of post-operative patients and in intensive care units, contributes to such high incidence of antibiotic resistance.

Our study reported less resistance to aminoglycosides: antibiotic resistance varied from 24% to 46% for amikacin and gentamicin, while only 24% of isolates were resistant against carbapenems including meropenem and imipenem in this study. Sid Ahmed et al., 2016, reported less resistance to aminoglycoside and carbapenem antibiotics against the pathogens in their study which is in contrast with our findings, possibly due to geological and periodic variations [31]. Another study conducted by Ejaz et al., 2021, reported more resistance to carbapenems as compared with aminoglycosides [32]. Haider et al., 2022, reported higher resistance rates for both aminoglycosides and carbapenems [33]. Similarly, Merah-Fergani et al., reported of both carbapenem and aminoglycoside resistance in clinical isolates [28]. However, there is significant data inconsistency due to variances in the species investigated, antibiotic abuse, self-medication, sample methodologies and geographic locations.

Our investigation found that piperacillin/tazobactam, meropenem, imipenem, gentamicin, amikacin, nitrofurantoin and fosfomycin were the most effective antibiotics against ESBL-producing isolates. Therefore, these antibiotics likely can be used to treat infections caused by these bacteria, whereas the remaining antibiotics lacked activity and so cannot be used as treatment options. Previous research conducted by different authors found that piperacillin/tazobactam, meropenem, imipenem, gentamicin, amikacin, nitrofurantoin

toin and fosfomycin were the most effective drugs for treating infections caused by ESBL producers [28,30–32,35–37]. Therefore, similar studies should continuously be conducted in developing countries to evaluate the performances of highly effective drugs which are commonly used to combat infections.

In this study, the molecular prevalence of ESBLs-coding genes including *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV} (99.26%), *bla*_{CTX-M} (91.2%), *bla*_{TEM} (61.8%), *bla*_{OXA} (39.3%) and *bla*_{SHV} (17.6%) among GNRs was remarkably similar to the different studies conducted in neighboring countries [38–41] and across the world [42]. The prevalences of *bla*_{CTX-M}, *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV} among *Escherichia coli*, *Klebsiella* species, *Acinetobacter* species and others varied from 66.7% to 92.0%, 60.3% to 72.2%, 16.7% to 40.8% and 14.4% to 22.2%, respectively. According to studies conducted in Iraq and neighboring countries, the *bla*_{CTX-M} gene was the dominant gene type in both *E. coli* and *Klebsiella pneumoniae* [43]. Currently, CTX-M enzymes have supplanted SHV and TEM enzymes as the predominant ESBL type in *E. coli* [44]. However, research conducted in Turkey and India revealed that TEM was the most prevalent type [45].

In this study, *bla*_{CTX-M} + *bla*_{TEM} (30.5%) was the most prevalent combination, followed by *bla*_{CTX-M} + *bla*_{OXA} + *bla*_{TEM} (14.0%), *bla*_{CTX-M} + *bla*_{OXA} (13.6%), *bla*_{CTX-M} + *bla*_{TEM} + *bla*_{SHV} (7.0%), *bla*_{CTX-M} + *bla*_{SHV} (2.2%), *bla*_{CTX-M} + *bla*_{OXA} + *bla*_{SHV} (2.2%) and *bla*_{OXA} + *bla*_{TEM} (1.8%). According to the previous study conducted in Nigeria, *bla*_{SHV} + *bla*_{TEM} + *bla*_{CTX-M} (70%) was the most prevalent combination, followed by *bla*_{TEM} + *bla*_{CTX-M} (15%), which contradicts our findings [43]. This study includes additional illustrations. Multiple genes (*bla*_{SHV}, *bla*_{TEM}, *bla*_{CTX-M}) found in the genomes of some of these isolates suggested the presence of resistance plasmids [40]. Polse et al., (2016) in Iraq found six genotype patterns in a small number of samples ($n = 50$), which was exceptionally lower than our study's ($n = 272$) 10 genotype patterns due to the small sample size [38]. Multiple ESBL genes in many ESBL-producing strains may have complex antimicrobial resistance, resulting in co-resistance to other antibiotic groups besides β -lactam antibiotics. In our study, *bla*_{TEM}, a broad-spectrum ESBL, was always combined with *bla*_{CTX-M}. According to this study, the occurrence of *bla*_{TEM} + *bla*_{CTX-M} + *bla*_{OXA} can result in resistance to penicillins, cephalosporins and fluoroquinolones. Due to the gradual increase of resistant strains to penicillin, cephalosporins and fluoroquinolones, which were recommended and commonly used to treat infections caused by ESBL-producing bacteria, are gradually experiencing setbacks. This is both alarming and grave for community and clinical settings. This emphasizes the significance of rational antibiotic therapy, reducing the dissemination of such strains in healthcare setting and awareness of the clinical manifestation of ESBL types. Gene sequencing may also provide the phylogenetic history that will play a vital role in overcoming the further dissemination of ESBL-corresponding genes [22,46].

In conclusion, *bla*_{CTX-M} was the most prevalent gene coding to ESBLs production among *E. coli*, *Klebsiella* species, *Acinetobacter* species and other clinical isolates, followed by *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV}. All possible genetic combinations of ESBLs-coding genes (*bla*_{CTX-M}, *bla*_{TEM}, *bla*_{OXA} and *bla*_{SHV}), except for *bla*_{OXA} + *bla*_{SHV}, were identified in 270 isolates of GNRs. The high rates of resistance among bacteria were due to the production of ESBLs, resulting β -lactam antibiotics (penicillins and cephalosporins) being ineffective, along with non- β -lactam antibiotics (fluoroquinolones and co-trimoxazole). Our study showed that piperacillin/tazobactam, carbapenems, aminoglycosides, nitrofurantoin and fosfomycin may be used to treat infections caused by ESBL-producing bacteria. Clinical microbiology labs should consistently use ESBL-identification tools to observe multidrug-resistant isolates and antibiograms to guide physicians and clinical staff for empirical therapy against infections. Infection prevention and control and antibiotic stewardship programs should be implemented in hospitals to limit the spread of resistant isolates.

4. Materials and Methods

4.1. Sample Collection, Transportation and Preservation

A total of two hundred and seventy-two ($n = 272$) ESBLs producing clinical isolates were isolated from urine, blood, throat aspiration, central venous catheter (CVC) tip, sputum, Percutaneous nephrostomy (PCN) urine, bronchial aspiration, ascitic fluid and cerebrospinal fluids. Samples were collected from patients admitted in different wards, i.e., out-patients door (OPD), emergency, nephrology, urology and the intensive care unit (ICU) of Multan Institute of Kidney Diseases Hospital, Multan, Pakistan (150-bed and single-specialty hospital) without age or gender discrimination in this study. Urine, sputum, fluids and PCN samples were collected in sterile containers and blood samples in culture vials (BD BACTEC™ Plus Aerobic/F, Franklin Lakes, NJ, USA) [47,48]. The samples were transported to the laboratory after collection by following different instructions, as urine samples within 2 to 4 h were placed on ice packs and blood culture vials (BD BACTEC™ Plus Aerobic/F, Franklin Lakes, NJ, USA) were held for 4 to 8 h at room temperature. After processing, urine samples were preserved at 2 °C to 8 °C in a refrigerator and blood culture vials at room temperature for one week [48].

This cross-sectional study was designed and conducted at Bahauddin Zakariya University, Multan from September 2020 to March 2021, and ethical approval was granted by the Institutional Review Board (IRB) of IMBB (Reference No. 334/A).

4.2. Sample Inoculation and Bacterial Identification

The urine samples were inoculated onto cysteine-lactose-electrolyte-deficient media (CLED, Oxoid, Basingstoke Hampshire, United Kingdom), and the remaining samples (throat aspiration, central venous catheter (CVC) tip, sputum, bronchial aspiration, ascitic fluid and cerebrospinal fluids) onto blood, chocolate and MacConkey agar (Oxoid, Basingstoke Hampshire, United Kingdom) plates [49]. The blood culture bottles were incubated at room temperature for 24 h followed by their subculture onto blood, chocolate and MacConkey agar. After inoculation, plates were placed at 37 °C in an incubator for overnight incubation. On the next day (after 24 h), plates were checked for bacterial growth and sub-cultured pure growth for making bacterial glycerol stock, gram staining, biochemical analysis for bacterial identification, antimicrobial susceptibility testing, and DNA extraction.

4.3. Bacterial Identification by Gram Staining and Biochemical Test

Pure bacterial growths were used for gram staining that was used to differentiate into gram-positive and gram-negative bacteria, either cocci or rods [50]. After confirmation of GNRs, analytical profile index 20 *Enterobacteriaceae* (API 20E, bioMérieux, Durham, NC, USA) was used to characterize the bacterial strain as *E. coli*, *Klebsiella* species, *Acinetobacter* species, *Proteus* species, *Serratia* species or *Salmonella* species [51] followed by antimicrobial susceptibility testing that was used to find which strains were resistant and susceptible to the antibiotics. Gram-positive bacteria were excluded in this study.

4.4. Antimicrobial Susceptibility Testing

The Kirby–Bauer disk diffusion method was used to determine the antimicrobial activity by measuring the zone of inhibition. In this study, 0.5 McFarland was used to make the inoculum by mixing bacterial colonies and normal saline in a test tube. This suspension was spread on Mueller–Hinton agar (MHA, Oxoid, Basingstoke Hampshire, United Kingdom) plates by cotton swab, following which antibiotic disks (Oxoid, Basingstoke Hampshire, United Kingdom) were dispensed on it. The zone of inhibition was measured and interpreted as resistant (R), intermediate (I) and susceptible (S) according to the guidelines given by Clinical and Laboratory Standards Institute (CLSI) [52]. The different antibiotics and their abbreviations and amounts used were as follows: ampicillin (AMP, 10 µg), amoxicillin/clavulanate (AMC, 10/20 µg), piperacillin/tazobactam (TZP, 100/10 µg), cefotaxime (CTX, 30 µg), sulbactam/cefoperazone (SCF), ceftazidime

(CAZ, 30 µg), meropenem (MEM, 10 µg), imipenem (IPM, 10 µg), gentamicin (CN, 10 µg), amikacin (AK, 30 µg), nalidixic acid (NA, 30 µg), norfloxacin (NOR, 10 µg), ciprofloxacin (CIP, 5 µg), trimethoprim/sulfamethoxazole (SXT, 1.2/23.5 µg), fosfomycin (FOS, 200 µg) and nitrofurantoin (F, 300 µg) used against *Enterobacteriaceae*.

4.5. Phenotypic Identification of ESBLs

The Phenotypic identification of the ESBLs was carried out by the double-disk synergy test (DDST) [53]. In this study, inoculum (0.5 McFarland) was spread over a MHA agar plate by cotton swab and then amoxicillin–clavulanate was dispensed (10 µg) in-between ceftazidime (30 µg) and cefotaxime (30 µg) at a distance of 30 mm away from each other. After overnight incubation at 37 °C, a clear extension of the edge of the inhibition zone was observed in the decreased inhibition of cefotaxime or ceftazidime with a clear-cut enhanced zone of inhibition in front of the amoxicillin–clavulanate disk, referred to as ESBLs positive test [54].

4.6. Molecular Detection of ESBLs

DNA extraction was carried out by the boiling method, in which one to two bacterial colonies were emulsified into distilled water in microcentrifuge tubes and then placed in water bath at 100 °C for 20 min. Microcentrifuge tubes were centrifuged for 5 min at 3000 rpm and the supernatant that can be used as DNA was removed and the precipitate was discarded [55]. DNA was preserved at −20 °C in a deep freezer. A total of 1% agarose gel containing ethidium bromide was used to confirm the DNA extraction under UV light.

*bla*_{CTX-M}, *bla*_{OXA}, *bla*_{TEM} and *bla*_{SHV} were identified by PCR, in which a specific primer sequence was used, as mentioned in Table 5. The PCR was carried out using 15 µL of reaction mixture containing 1 µL (5 µM) of each forward and reverse primer, 7.5 µL of master mix (Vazyme Biotech Co., Nanjing, China), 2.5 µL of DNA (125 ng) and 3 µL of distilled water. Bio-Rad T100 Thermal Cycler (Hercules, CA, USA) conditions were adjusted as: first cycle at 94 °C for 5 min followed by 35 cycles at 94 °C for 30 s, 50 °C (*bla*_{CTX-M})/56 °C (*bla*_{OXA}, *bla*_{TEM}, and *bla*_{SHV}) for 40 s, 72 °C for 40 s and a final extension at 72 °C for 5 min. The PCR product was analysed by using 1.2% agarose gel with staining dye (ethidium bromide) and 220 volts were applied for 40 min before visualization under UV light (Figure 1).




Figure 1. Visualization of DNA bands by gel electrophoresis. (a) Lane-NC and PC stand for negative and positive control, respectively. Lane-12 is showing band of 392 bp, which is related to *bla*_{SHV} gene, and lane-1, -2, -3, -4, -5, -6, -7, -8, -9, -10 and -11 are negative for *bla*_{SHV} gene. (b) Lane-NC and PC stand for negative and positive control, respectively. Lane-1, -2, -3, -4 and -6 are showing bands of 860 bp, which is related to *bla*_{TEM} gene. Lane-7 and -10 are showing bands of 619 bp, which is related to *bla*_{OXA} gene. Lane-8, -9 and -11 are showing both 860 bp and 619 bp bands, which are related to *bla*_{TEM} and *bla*_{OXA}, respectively. Lane-5 has no band. (c) Lane-NC and PC stand for negative and positive control, respectively. Lane-1 to -12 are showing bands of 593 bp, which is related to *bla*_{CTX-M} gene.

Table 5. Primer used for molecular identification of ESBLs by PCR.

Target Gene		Primer Sequence	Product Size	Annealing Temperature (°C)	References
<i>bla</i> _{TEM}	F	5'-TCAACATTTCCGTGTCG-3'	860	56	[56]
	R	5'-CTGACAGTTACCAATGCTTA-3'			
<i>bla</i> _{CTX-M}	F	5'-ATGTGCAGYACCAGTAARGT-3'	593	50	[57]
	R	5'-TGGGTRAARTARGTSACCAGA-3'			
<i>bla</i> _{OXA}	F	5'-ATATCTCTACTGTTGCATCTCC-3'	619	56	[58]
	R	5'-AAACCCTTCAAACCATCC-3'			
<i>bla</i> _{SHV}	F	5'-AGGATTGACTGCCTTTTTG-3'	392	56	[58]
	R	5'-ATTTGCTGATTTTCGCTCG-3'			

4.7. Quality Control

Different American type culture collection (ATCC) strains (Manassas, Virginia, near Washington, DC, USA) were used to check the accuracies, precisions and reproducibilities of the growth-supporting characteristics of the prepared media (CLED agar, Blood agar, Chocolate agar, MacConkey agar and MHA agar), gram staining, biochemical tests (oxidase test, catalase test, indole test, urease test, citrate test and TSI test) [49]. The accuracy of the susceptibility testing was confirmed by dispensing antibiotics against ATCC strains, and their results were interpreted according to CLSI guidelines [59]. The different strains used in this study were *Escherichia coli* (ATCC 25922), *Proteus mirabilis* (ATCC 35659), *Pseudomonas aeruginosa* (ATCC 8427) and *Staphylococcus aureus* (ATCC 25923).

4.8. Statistical Analysis

Statistical analysis was carried out using the chi-square test on the data represented in this study. A tool used for statistical analysis was GraphPad Prism 9 (GraphPad Software, San Diego, CA, USA). A *p*-value ≤ 0.05 was representative of the significance of data statistically.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/antibiotics12010029/s1>, Supplementary data file: Detail information of socio-demographic data of all clinical samples, bacterial isolates, antibiotic resistance/susceptibility & antibiotic resistance gene analysis.

Author Contributions: Conceptualization, M.M.I. and A.S.; methodology, M.D.I.; investigation, M.M.I., R.R., M.D.I.; data curation, A.S., M.M.I., R.R. and M.D.I.; writing—original draft preparation, M.M.I., A.S., R.R. and M.D.I.; writing—review and editing, A.S. and M.M.I.; supervision, A.S. and M.D.I. All authors have read and agreed to the published version of the manuscript.

Funding: The study was funded and supported by the departmental budget of the Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University & Multan Institute of Kidney Diseases (MIKD), Multan, Pakistan. The authors further appreciate the support provided by ORIC, Bahauddin Zakariya University, Multan, Pakistan, through Project No. ORIC/2021/143.

Institutional Review Board Statement: This study was designed and conducted at “Multan Institute of Kidney Diseases (MIKD)” Hospital, Multan, Pakistan and Institute of Molecular Biology and Biotechnology (IMBB), Bahauddin Zakariya University (BZU), Multan, Pakistan. All ethical approvals were obtained from the university board of studies for ethical research (case number IMBB-78632).

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest. The authors certify that they have NO affiliations with or involvement in any organization or entity with any financial or non-financial interest in the subject matter or materials described in this manuscript.

References

1. Bush, K.; Jacoby, G.A.; Medeiros, A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. *Antimicrob. Agents Chemother.* **1995**, *39*, 1211–1233. [[CrossRef](#)] [[PubMed](#)]
2. Ghafourian, S.; Sadeghifard, N.; Soheili, S.; Sekawi, Z. Extended spectrum beta-lactamases: Definition, classification and epidemiology. *Curr. Issues Mol. Biol.* **2015**, *17*, 11–22. [[PubMed](#)]
3. Ruppé, É.; Woerther, P.-L.; Barbier, F. Mechanisms of antimicrobial resistance in Gram-negative bacilli. *Ann. Intensive Care* **2015**, *5*, 21. [[CrossRef](#)] [[PubMed](#)]
4. Sutton, S.S. What are extended-spectrum beta-lactamases? *J. Am. Acad. PAs* **2014**, *27*, 14–17. [[CrossRef](#)] [[PubMed](#)]
5. Chong, Y.; Shimoda, S.; Yakushiji, H.; Ito, Y.; Miyamoto, T.; Kamimura, T.; Shimono, N.; Akashi, K. Community spread of extended-spectrum β -lactamase-producing *Escherichia coli*, *Klebsiella pneumoniae* and *Proteus mirabilis*: A long-term study in Japan. *J. Med. Microbiol.* **2013**, *62*, 1038–1043. [[CrossRef](#)]
6. Kassakian, S.Z.; Mermel, L.A. Changing epidemiology of infections due to extended spectrum beta-lactamase producing bacteria. *Antimicrob. Resist. Infect. Control* **2014**, *3*, 9. [[CrossRef](#)]
7. Aidara-Kane, A.; Angulo, F.J.; Conly, J.M.; Minato, Y.; Silbergeld, E.K.; McEwen, S.A.; Collignon, P.J. World Health Organization (WHO) guidelines on use of medically important antimicrobials in food-producing animals. *Antimicrob. Resist. Infect. Control* **2018**, *7*, 7. [[CrossRef](#)]
8. Datta, N.; Kontomichalou, P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. *Nature* **1965**, *208*, 239–241. [[CrossRef](#)]
9. Knothe, H.; Shah, P.; Krcmery, V.; Antal, M.; Mitsunashi, S. Transferable resistance to cefotaxime, cefoxitin, cefamandole and cefuroxime in clinical isolates of *Klebsiella pneumoniae* and *Serratia marcescens*. *Infection* **1983**, *11*, 315–317. [[CrossRef](#)]
10. Philippon, A.; Labia, R.; Jacoby, G. Extended-spectrum beta-lactamases. *Antimicrob. Agents Chemother.* **1989**, *33*, 1131–1136. [[CrossRef](#)]
11. Livermore, D.M. Defining an extended-spectrum β -lactamase. *Clin. Microbiol. Infect.* **2008**, *14*, 3–10. [[CrossRef](#)]
12. Ambler, R.P.; Coulson, A.F.; Frère, J.-M.; Ghuysen, J.-M.; Joris, B.; Forsman, M.; Levesque, R.C.; Tiraby, G.; Waley, S.G. A standard numbering scheme for the class A beta-lactamases. *Biochem. J.* **1991**, *276 Pt 1*, 269. [[CrossRef](#)]
13. Thenmozhi, S.; Moorthy, K.; Sureshkumar, B.; Suresh, M. Antibiotic resistance mechanism of ESBL producing Enterobacteriaceae in clinical field: A review. *Int. J. Pure Appl. Biosci.* **2014**, *2*, 207–226.
14. Adamski, C.J.; Cardenas, A.M.; Brown, N.G.; Horton, L.B.; Sankaran, B.; Prasad, B.V.; Gilbert, H.F.; Palzkill, T. Molecular basis for the catalytic specificity of the CTX-M extended-spectrum β -lactamases. *Biochemistry* **2015**, *54*, 447–457. [[CrossRef](#)]
15. Shaikh, S.; Fatima, J.; Shakil, S.; Rizvi, S.M.D.; Kamal, M.A. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. *Saudi J. Biol. Sci.* **2015**, *22*, 90–101. [[CrossRef](#)]
16. Balkhed, Å.Ö.; Tärnberg, M.; Monstein, H.-J.; Hällgren, A.; Hanberger, H.; Nilsson, L.E. High frequency of co-resistance in CTX-M-producing *Escherichia coli* to non-beta-lactam antibiotics, with the exceptions of amikacin, nitrofurantoin, colistin, tigecycline, and fosfomycin, in a county of Sweden. *Scand. J. Infect. Dis.* **2013**, *45*, 271–278. [[CrossRef](#)]
17. Lahlaoui, H.; Khalifa, A.B.H.; Moussa, M.B. Epidemiology of Enterobacteriaceae producing CTX-M type extended spectrum β -lactamase (ESBL). *Med. Mal. Infect.* **2014**, *44*, 400–404. [[CrossRef](#)]
18. Mojtahedi, A. The presence of extended-spectrum β -lactamase as a risk factor for MDR in clinical isolation of *Escherichia coli*. *Trop. Biomed.* **2017**, *34*, 98–109.
19. Kapil, A. The challenge of antibiotic resistance: Need to contemplate. *Indian J. Med. Res.* **2005**, *121*, 83.
20. Idrees, M.M.; Saeed, A. Genetic and molecular mechanisms of multidrug-resistance in uropathogens and novel therapeutic combat. In *Biochemistry of Drug Resistance*; Springer: Berlin/Heidelberg, Germany, 2021; pp. 505–538.
21. Moo, C.-L.; Yang, S.-K.; Yusoff, K.; Ajat, M.; Thomas, W.; Abushelaibi, A.; Lim, S.-H.-E.; Lai, K.-S. Mechanisms of antimicrobial resistance (AMR) and alternative approaches to overcome AMR. *Curr. Drug Discov. Technol.* **2020**, *17*, 430–447. [[CrossRef](#)]
22. Argimón, S.; Yeats, C.A.; Goater, R.J.; Abudahab, K.; Taylor, B.; Underwood, A.; Sánchez-Busó, L.; Wong, V.K.; Dyson, Z.A.; Nair, S. A global resource for genomic predictions of antimicrobial resistance and surveillance of *Salmonella* Typhi at pathogenwatch. *Nat. Commun.* **2021**, *12*, 2879. [[CrossRef](#)] [[PubMed](#)]
23. Teklu, D.S.; Negeri, A.A.; Legese, M.H.; Bedada, T.L.; Woldemariam, H.K.; Tullu, K.D. Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia. *Antimicrob. Resist. Infect. Control* **2019**, *8*, 39. [[CrossRef](#)] [[PubMed](#)]
24. Prasad, B.V.; Sridhar, V. Diversity Studies in Yellow Pericarp Sorghum [*Sorghum bicolor* (L.) Moench] Genotypes for Yield Attributes. *Int. J. Curr. Microbiol. Appl. Sci.* **2019**, *8*, 361–366. [[CrossRef](#)]
25. Ahmed, Y.M.A.; Mohammed El Imam, M.; Khalid, K.E.; Mohamed, B.A.; Elhag, K.M. Phenotype and genotype of extendedspectrum-beta-lactamases in Sudanese patients with UTI. *Basic Res. J. Microbiol.* **2014**, *3*, 1–5.
26. Hijazi, S.; Fawzi, M.; Ali, F.; Abd El Galil, K. Prevalence and characterization of extended-spectrum beta-lactamases producing Enterobacteriaceae in healthy children and associated risk factors. *Ann. Clin. Microbiol. Antimicrob.* **2016**, *15*, 3. [[CrossRef](#)]
27. Salvia, T.; Dolma, K.G.; Dhakal, O.P.; Khandelwal, B.; Singh, L.S. Phenotypic Detection of ESBL, AmpC, MBL, and Their Co-occurrence among MDR Enterobacteriaceae Isolates in a Tertiary Care Hospital in Sikkim, India. *J. Lab. Physicians* **2022**, *14*, 329–335.

28. Merah-Fergani, O.; Sebahia, M.; Berrazeg, M.; Amraoui, R.; Diene, S.M.; Rolain, J.-M. Occurrence and Diversity of Extended-Spectrum β -lactamases in Clinical Isolates of Enterobacteriaceae in A Tertiary Care Hospital in Algeria. *J. Infect. Dis. Antimicrob. Agents* **2022**, *39*, 1–14.
29. Casellas, J.; Goldberg, M. Incidence of strains producing extended spectrum β -lactamases in Argentina. *Infection* **1989**, *17*, 434–436. [[CrossRef](#)]
30. Aksaray, S.G.S.; Dokuzoğuz, B.; Güvener, E.; Yücesoy, M.; Yuluğ, N.; Kocagöz, S.; Ünal, S.; Çetin, S.; Çalangu, S.; Günaydın, M. Surveillance of antimicrobial resistance among gram-negative isolates from intensive care units in eight hospitals in Turkey. *J. Antimicrob. Chemother.* **2000**, *45*, 695–699. [[CrossRef](#)]
31. Sid Ahmed, M.A.; Bansal, D.; Acharya, A.; Elmi, A.A.; Hamid, J.M.; Sid Ahmed, A.M.; Chandra, P.; Ibrahim, E.; Sultan, A.A.; Doiphode, S. Antimicrobial susceptibility and molecular epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae from intensive care units at Hamad Medical Corporation, Qatar. *Antimicrob. Resist. Infect. Control* **2016**, *5*, 4. [[CrossRef](#)]
32. Ejaz, H.; Younas, S.; Abosalif, K.O.; Junaid, K.; Alzahrani, B.; Alsrhani, A.; Abdalla, A.E.; Ullah, M.I.; Qamar, M.U.; Hamam, S.S. Molecular analysis of bla SHV, bla TEM, and bla CTX-M in extended-spectrum β -lactamase producing Enterobacteriaceae recovered from fecal specimens of animals. *PLoS ONE* **2021**, *16*, e0245126. [[CrossRef](#)]
33. Haider, M.H.; McHugh, T.D.; Roulston, K.; Arruda, L.B.; Sadouki, Z.; Riaz, S. Detection of carbapenemases blaOXA48-blaKPC-blaNDM-blaVIM and extended-spectrum- β -lactamase blaOXA1-blaSHV-blaTEM genes in Gram-negative bacterial isolates from ICU burns patients. *Ann. Clin. Microbiol. Antimicrob.* **2022**, *21*, 18. [[CrossRef](#)]
34. Thomson, K.S.; Sanders, C.C. Detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae: Comparison of the double-disk and three-dimensional tests. *Antimicrob. Agents Chemother.* **1992**, *36*, 1877–1882. [[CrossRef](#)]
35. Bullens, M.; de Cerqueira Melo, A.; Raziq, S.; Lee, J.; Khalid, G.; Khan, S.; Zada, A.; Wailly, Y.; Zeshan, S.; Saad, N. Antibiotic resistance in patients with urinary tract infections in Pakistan. *Public Health Action* **2022**, *12*, 48–52. [[CrossRef](#)]
36. Mazzariol, A.; Bazaj, A.; Cornaglia, G. Multi-drug-resistant Gram-negative bacteria causing urinary tract infections: A review. *J. Chemother.* **2017**, *29* (Suppl. 1), 2–9. [[CrossRef](#)]
37. Silver, L.L. Fosfomycin: Mechanism and resistance. *Cold Spring Harb. Perspect. Med.* **2017**, *7*, a025262. [[CrossRef](#)]
38. Polse, R.F.; Yousif, S.Y.; Assafi, M.S. Prevalence and molecular characterization of extended spectrum beta-Lactamases-producing uropathogenic Escherichia coli isolated in Zakho, Iraq. *J. Microbiol. Infect. Dis.* **2016**, *6*, 163–167.
39. Alqasim, A.; Abu Jaffal, A.; Alyousef, A.A. Prevalence of multidrug resistance and extended-spectrum β -lactamase carriage of clinical uropathogenic Escherichia coli isolates in Riyadh, Saudi Arabia. *Int. J. Microbiol.* **2018**, *2018*, 3026851. [[CrossRef](#)]
40. Mashwal, F.A.; El Safi, S.H.; George, S.K.; Adam, A.A.; Jebakumar, A.Z. Incidence and molecular characterization of the extended spectrum beta lactamase-producing Escherichia coli isolated from urinary tract infections in Eastern Saudi Arabia. *Saudi Med. J.* **2017**, *38*, 811. [[CrossRef](#)]
41. Jena, J.; Sahoo, R.K.; Debata, N.K.; Subudhi, E. Prevalence of TEM, SHV, and CTX-M genes of extended-spectrum β -lactamase-producing Escherichia coli strains isolated from urinary tract infections in adults. *3 Biotech* **2017**, *7*, 244. [[CrossRef](#)]
42. Ogefere, H.O.; Aigbiremwen, P.A.; Omoregie, R. Extended-spectrum beta-lactamase (ESBL)-producing Gram-negative isolates from urine and wound specimens in a tertiary health facility in southern Nigeria. *Trop. J. Pharm. Res.* **2015**, *14*, 1089–1094. [[CrossRef](#)]
43. Nwafuluaku, I.G.; Agbakoba, N.R.; Ushie, S.N.; Dilibe, E.A. Prevalence and molecular characterization of extended spectrum beta-lactamase producing uropathogenic Escherichia coli in a tertiary health care facility in Anambra State, Nigeria. *World J. Adv. Res. Rev.* **2021**, *11*, 300–311. [[CrossRef](#)]
44. Cantón, R.; Coque, T.M. The CTX-M β -lactamase pandemic. *Curr. Opin. Microbiol.* **2006**, *9*, 466–475. [[CrossRef](#)] [[PubMed](#)]
45. Bali, E.B.; Acik, L.; Sultan, N. Phenotypic and molecular characterization of SHV, TEM, CTX-M and extended-spectrum beta-lactamase produced by Escherichia coli, Acinobacter baumannii and Klebsiella isolates in a Turkish hospital. *Afr. J. Microbiol. Res.* **2010**, *4*, 650–654.
46. Amoutzias, G.D.; Nikolaidis, M.; Hesketh, A. The Notable Achievements and the Prospects of Bacterial Pathogen Genomics. *Microorganisms* **2022**, *10*, 1040. [[CrossRef](#)]
47. Rohner, P.; Pepey, B.; Auckenthaler, R. Advantage of combining resin with lytic BACTEC blood culture media. *J. Clin. Microbiol.* **1997**, *35*, 2634–2638. [[CrossRef](#)]
48. Sánchez-Romero, M.I.; Moya, J.M.G.-L.; López, J.J.G.; Mira, N.O. Collection, transport and general processing of clinical specimens in Microbiology laboratory. *Enferm. Infecc. Microbiol. Clin.* **2019**, *37*, 127–134. [[CrossRef](#)]
49. Cheesbrough, M. *District Laboratory Practice in Tropical Countries, Part 2*; Cambridge University Press: Cambridge, UK, 2005.
50. Coico, R. Gram staining. *Curr. Protoc. Microbiol.* **2006**. [[CrossRef](#)]
51. Holmes, B.; Willcox, W.; Lapage, S. Identification of Enterobacteriaceae by the API 20E system. *J. Clin. Pathol.* **1978**, *31*, 22–30. [[CrossRef](#)]
52. Humphries, R.; Bobenchik, A.M.; Hindler, J.A.; Schuetz, A.N. Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100. *J. Clin. Microbiol.* **2021**, *59*, e0021321. [[CrossRef](#)]
53. Jarlier, V.; Nicolas, M.-H.; Fournier, G.; Philippon, A. Extended broad-spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in Enterobacteriaceae: Hospital prevalence and susceptibility patterns. *Clin. Infect. Dis.* **1988**, *10*, 867–878. [[CrossRef](#)]

54. Drieux, L.; Brossier, F.; Sougakoff, W.; Jarlier, V. Phenotypic detection of extended-spectrum β -lactamase production in Enterobacteriaceae: Review and bench guide. *Clin. Microbiol. Infect.* **2008**, *14*, 90–103. [[CrossRef](#)]
55. Ahmed, O.B.; Dablood, A. Quality improvement of the DNA extracted by boiling method in gram negative bacteria. *Int. J. Bioassays* **2017**, *6*, 5347–5349. [[CrossRef](#)]
56. Schlesinger, J.; Navon-Venezia, S.; Chmelnitsky, I.; Hammer-Munz, O.; Leavitt, A.; Gold, H.S.; Schwaber, M.J.; Carmeli, Y. Extended-spectrum beta-lactamases among Enterobacter isolates obtained in Tel Aviv, Israel. *Antimicrob. Agents Chemother.* **2005**, *49*, 1150–1156. [[CrossRef](#)]
57. Pallecchi, L.; Malossi, M.; Mantella, A.; Gotuzzo, E.; Trigoso, C.; Bartoloni, A.; Paradisi, F.; Kronvall, G.R.; Rossolini, G.M. Detection of CTX-M-type β -lactamase genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. *Antimicrob. Agents Chemother.* **2004**, *48*, 4556–4561. [[CrossRef](#)]
58. Colom, K.; Pérez, J.; Alonso, R.; Fernández-Aranguiz, A.; Lariño, E.; Cisterna, R. Simple and reliable multiplex PCR assay for detection of bla TEM, bla SHV and bla OXA-1 genes in Enterobacteriaceae. *FEMS Microbiol. Lett.* **2003**, *223*, 147–151. [[CrossRef](#)]
59. Weinstein, M.P.; Lewis, J.S. The clinical and laboratory standards institute subcommittee on antimicrobial susceptibility testing: Background, organization, functions, and processes. *J. Clin. Microbiol.* **2020**, *58*, e01864-19. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.